远端利尿剂与限盐治疗CKD高血压的随机试验
本研究为6周随机开放交叉试验,比较阿米洛利/氢氯噻嗪(5mg/50mg每日)与限盐(60mmol/日)对CKD G3-G4期高血压患者的降压效果。26例患者完成两种治疗,结果显示利尿剂在降低24小时收缩压和细胞外液方面非劣于限盐,且利尿剂敏感性在CKD中得以维持,尽管其肾脏清除率降低。
要点
- 远端利尿剂降压效果不劣于限盐,且对细胞外液和eGFR影响更显著。
- CKD患者尽管利尿剂清除率降低,但其对体重和血压的效应仍维持。
- 利尿剂治疗中4例出现轻度低钠血症,需监测血钠。
核心结论
- 在CKD G3-G4期高血压患者中,远端利尿剂在降低血压和细胞外容量方面非劣于限盐。
- 尽管eGFR较低和血浆吲哚硫酸较高与利尿剂清除率降低相关,但利尿剂对体重和血压的效应仍维持。
研究设计与样本
- 6周随机开放交叉试验,比较阿米洛利/氢氯噻嗪(5mg/50mg每日)与限盐(60mmol/日)。
- 26例CKD G3或G4期高血压患者完成两种治疗,平均eGFR为39 ml/min/1.73 m2。
- 随机化前停用降压药2周。
主要发现
- 限盐使钠排泄从160降至64 mmol/日。
- 利尿剂使24小时收缩压从138降至124 mm Hg,限盐从134降至129 mm Hg,利尿剂组降幅更大。
- 利尿剂对细胞外水、eGFR、血浆肾素和醛固酮的影响显著大于限盐。
- 两种干预均相似降低体重和NT-proBNP,均未显著降低白蛋白尿,但利尿剂显著降低尿血管紧张素原和β2-微球蛋白排泄。
- 利尿剂治疗期间,4例患者发生轻度低钠血症;较高PGE2排泄与较低自由水清除率相关。
临床怎么用
- 对于CKD G3-G4期高血压患者,远端利尿剂可作为限盐之外的有效降压选择。
- 使用远端利尿剂时需监测血钠,警惕低钠血症。
局限性
- 样本量较小(26例),为开放标签设计。
- 干预时间较短(6周),长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distal diuretics are considered less effective than loop diuretics in CKD. However, data to support this perception are limited. METHODS: To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducing BP in patients with CKD stage G3 or G4 and hypertension, we conducted a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol per day). Antihypertension medication was discontinued for a 2-week period before randomization. We analyzed effects on BP, kidney function, and fluid balance and related this to renal clearance of diuretics. RESULTS: A total of 26 patients (with a mean eGFR of 39 ml/min per 1.73 m2) completed both treatments. Dietary sodium restriction reduced sodium excretion from 160 to 64 mmol per day. Diuretics produced a greater reduction in 24-hour systolic BP (SBP; from 138 to 124 mm Hg) compared with sodium restriction (from 134 to 129 mm Hg), as well as a significantly greater effect on extracellular water, eGFR, plasma renin, and aldosterone. Both interventions resulted in a similar decrease in body weight and NT-proBNP. Neither approaches decreased albuminuria significantly, whereas diuretics did significantly reduce urinary angiotensinogen and β2-microglobulin excretion. Although lower eGFR and higher plasma indoxyl sulfate correlated with lower diuretic clearance, the diuretic effects on body weight and BP at lower eGFR were maintained. During diuretic treatment, higher PGE2 excretion correlated with lower free water clearance, and four patients developed mild hyponatremia. CONCLUSIONS: Distal diuretics are noninferior to dietary sodium restriction in reducing BP and extracellular volume in CKD. Diuretic sensitivity in CKD is maintained despite lower diuretic clearance. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease (DD), NCT02875886.
引用
- Bovée DM, Visser WJ, Middel I, et al. A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. J Am Soc Nephrol. 2020. PMID: 31996411. doi:10.1681/ASN.2019090905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。